| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3345 | 2014 |
| Development of a second-generation antiandrogen for treatment of advanced prostate cancer C Tran, S Ouk, NJ Clegg, Y Chen, PA Watson, V Arora, J Wongvipat, ... Science 324 (5928), 787-790, 2009 | 2660 | 2009 |
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology 26 (7), 1148-1159, 2008 | 2430 | 2008 |
| Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a … ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ... The lancet oncology 15 (7), 700-712, 2014 | 1575 | 2014 |
| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 1485 | 2021 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016 | 1342 | 2016 |
| Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ... The Lancet 375 (9724), 1437-1446, 2010 | 1303 | 2010 |
| Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B Y Sun, J Campisi, C Higano, TM Beer, P Porter, I Coleman, L True, ... Nature medicine 18 (9), 1359-1368, 2012 | 858 | 2012 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 856* | 2018 |
| Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant … TM Beer, ED Kwon, CG Drake, K Fizazi, C Logothetis, G Gravis, V Ganju, ... Journal of Clinical Oncology 35 (1), 40-47, 2017 | 736 | 2017 |
| Genomic hallmarks and structural variation in metastatic prostate cancer DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ... Cell 174 (3), 758-769. e9, 2018 | 652 | 2018 |
| Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study R Aggarwal, J Huang, JJ Alumkal, L Zhang, FY Feng, GV Thomas, ... Journal of Clinical Oncology 36 (24), 2492-2503, 2018 | 623 | 2018 |
| How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30 EK Fromme, KM Eilers, M Mori, YC Hsieh, TM Beer Journal of Clinical Oncology 22 (17), 3485-3490, 2004 | 597 | 2004 |
| Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study SF Slovin, CS Higano, O Hamid, S Tejwani, A Harzstark, JJ Alumkal, ... Annals of Oncology 24 (7), 1813-1821, 2013 | 587 | 2013 |
| Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... European urology 71 (2), 151-154, 2017 | 465 | 2017 |
| Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer ML Zhu, CM Horbinski, M Garzotto, DZ Qian, TM Beer, N Kyprianou Cancer research 70 (20), 7992-8002, 2010 | 414 | 2010 |
| Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ... JNCI: Journal of the National Cancer Institute 109 (12), djx118, 2017 | 390 | 2017 |
| Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer JN Graff, JJ Alumkal, CG Drake, GV Thomas, WL Redmond, M Farhad, ... Oncotarget 7 (33), 52810, 2016 | 380 | 2016 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 380 | 2015 |
| Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT … TM Beer, CW Ryan, PM Venner, DP Petrylak, GS Chatta, JD Ruether, ... Journal of Clinical Oncology 25 (6), 669-674, 2007 | 377 | 2007 |
M GarzottoProfessor of Urology and Radiation Medicine, Oregon Health Science University在 ohsu.edu 的电子邮件经过验证
